IDEXX Laboratories (IDXX) has been drawing considerable attention on Wall Street. Overall, a positive outlook on company profits, rising revenue, and an upward trajectory in stock prices, further propelled by strong Q2 & Q3 earnings. Many financial institutions have variably trimmed, increased, or sold their IDXX positions, including royal names like
Voya,
Franklin Street Advisors, and
Orion Portfolio Solutions. Analysts have varying opinions on the company's valuation, with firms such as
Barclays and
BofA Securities maintaining their respective overweight and hold ratings. The stock rallied year-to-date due to the company’s robust financials and upbeat Q3 results. A significant driving factor behind the success of IDXX is its booming diagnostics business, especially with the stimulus of a 'puppy boom' elevating the demand in pet healthcare.
IDEXX Laboratories's performance has been outshining its sector, posting a 97% return in 3 years, significantly outpacing competitors such as Zoetis. The future prospects for the company appear strong after releasing its 2024 Corporate Responsibility Report, highlighting progress against its goals. Therefore, whether an investor entered 10 or 20 years ago, their investment would have substantially grown today.
Idexx Laboratories IDXX News Analytics from Wed, 09 Jul 2025 07:00:00 GMT to Sat, 20 Dec 2025 13:44:02 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor 5
